CN102458460B - 纯化蛋白复合物的方法 - Google Patents

纯化蛋白复合物的方法 Download PDF

Info

Publication number
CN102458460B
CN102458460B CN201080031703.0A CN201080031703A CN102458460B CN 102458460 B CN102458460 B CN 102458460B CN 201080031703 A CN201080031703 A CN 201080031703A CN 102458460 B CN102458460 B CN 102458460B
Authority
CN
China
Prior art keywords
virus
stress protein
protein
buffer
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080031703.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102458460A (zh
Inventor
卡米洛·科拉科
科林·理查德·比格内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of CN102458460A publication Critical patent/CN102458460A/zh
Application granted granted Critical
Publication of CN102458460B publication Critical patent/CN102458460B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080031703.0A 2009-06-19 2010-06-21 纯化蛋白复合物的方法 Active CN102458460B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910591.7A GB0910591D0 (en) 2009-06-19 2009-06-19 Method for the purification of protein complexes
GB0910591.7 2009-06-19
PCT/GB2010/051023 WO2010146401A1 (en) 2009-06-19 2010-06-21 Method for the purification of protein complexes

Publications (2)

Publication Number Publication Date
CN102458460A CN102458460A (zh) 2012-05-16
CN102458460B true CN102458460B (zh) 2018-01-30

Family

ID=40941082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080031703.0A Active CN102458460B (zh) 2009-06-19 2010-06-21 纯化蛋白复合物的方法

Country Status (9)

Country Link
US (1) US10040820B2 (enExample)
EP (1) EP2442825B1 (enExample)
JP (1) JP5778666B2 (enExample)
CN (1) CN102458460B (enExample)
AU (1) AU2010261505B2 (enExample)
GB (1) GB0910591D0 (enExample)
IN (1) IN2012DN00250A (enExample)
WO (1) WO2010146401A1 (enExample)
ZA (1) ZA201200420B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201508401TA (en) * 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
CN103687616A (zh) * 2011-07-21 2014-03-26 生物技术工具公司 Dnak制剂
CA3066247A1 (en) 2017-06-07 2018-12-13 University Of Maryland, Baltimore County Factory-on-a-chip for production of biologically derived medicines/biopharmaceuticals/biologics/ biotherapeutics
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
EP0851765A4 (en) * 1995-09-13 2000-01-19 Univ Fordham THERAPEUTIC AND PROPHYLACTIC PROCESSES THAT USE HEAT SHOCK PROTEINS
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
GB9818133D0 (en) 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
GB9919734D0 (en) 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
GB9919733D0 (en) 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
WO2002028407A1 (en) 2000-09-29 2002-04-11 University Of Connecticut Health Center Methods of recovering heat shock proteins and complexes thereof
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) * 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
CN1665533A (zh) 2002-05-02 2005-09-07 康涅狄格大学健康中心 热激蛋白用于增强抗体疗法功效的用途
EP2145896A3 (en) * 2003-11-12 2010-03-31 Alfa Biogene International B.V. Recovery of a heat shock protein
GB0816242D0 (en) 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes

Also Published As

Publication number Publication date
ZA201200420B (en) 2018-11-28
JP2012530123A (ja) 2012-11-29
JP5778666B2 (ja) 2015-09-16
IN2012DN00250A (enExample) 2015-05-01
GB0910591D0 (en) 2009-07-29
EP2442825A1 (en) 2012-04-25
CN102458460A (zh) 2012-05-16
EP2442825B1 (en) 2017-11-08
AU2010261505A1 (en) 2012-01-19
US10040820B2 (en) 2018-08-07
AU2010261505B2 (en) 2015-02-05
US20120135029A1 (en) 2012-05-31
WO2010146401A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
EP2341926B1 (en) Method for purifying heat shock protein complexes
Hajam et al. Bacterial ghosts as adjuvants: mechanisms and potential
CN102458460B (zh) 纯化蛋白复合物的方法
TW202039587A (zh) 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
US11285204B2 (en) Tobamovirus-based virus-like particles and vaccines
CA2674458A1 (en) Fusion protein
Qu et al. Immunogenicity and vaccine efficacy boosted by engineering human heavy chain ferritin and chimeric hepatitis B virus core nanoparticles
Mizukami et al. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors
WO2005042564A1 (en) Flagellin fusion proteins as adjuvants or vaccines and methods of use
CN107207614A (zh) 嵌合蛋白
EP3231441A1 (en) Novel protein structure produced by effective antibody used for immunization
US20240207380A1 (en) Novel peptide targeting dendritic cells, and composition for treating cancer comprising same
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
EP2370100B1 (en) Peptide adjuvants
JP2013545733A (ja) ヒト免疫不全ウィルス（ｈｉｖ）の組換えエンベロープ蛋白質及びそれを含むワクチン
CN105622762A (zh) 一种牛趋化因子介导的o型口蹄疫靶向性复合表位蛋白及疫苗
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
RU2824195C1 (ru) Мультиэпитопный полипептид для иммунизации против Mycobacterium tuberculosis
JP7513303B2 (ja) 腫瘍免疫増強剤、その調製方法および適用
US10525127B2 (en) P14.7 protein and uses thereof as vaccine adjuvant
Dey et al. Heat Shock Protein as an Adjuvant in Veterinary Vaccines
CN111658770A (zh) P14.7蛋白质及其作为疫苗佐剂的用途
EP3135295A1 (en) Coupling of borrelial protein bb0689 to virus-like particles for generation of lyme disease vaccine
MX2013001626A (es) Metodo de elaboracion de una vacuna recombinante contra la fiebre de embarque usando proteinas recombinantes de mannheimia haemolytica unidas a cuerpos celulares.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant